Keyphrases
Potential Therapeutics
100%
Prognostic Biomarker
100%
Therapeutic Biomarkers
100%
NY-ESO-1
100%
Triple-negative Breast Carcinoma
100%
PRAME
100%
Triple-negative Breast Cancer
62%
Progression-free Survival
50%
Pathological Complete Response
37%
Residual Cancer Burden
37%
Metastatic Disease
25%
Early Metastatic
25%
H-score
25%
High-level Expression
12%
Clinical Outcomes
12%
Putative Drug Targets
12%
Breast Cancer Patients
12%
Neoadjuvant Chemotherapy
12%
Retrospective Cohort Study
12%
Low Risk
12%
Logistic Regression
12%
Cox Proportional Hazards Model
12%
Cancer-testis Antigen
12%
Response to Neoadjuvant Chemotherapy
12%
Early Metastasis
12%
Metastasis Cancer
12%
Chemotherapy-free
12%
Medicine and Dentistry
Biological Marker
100%
Triple Negative Breast Cancer
100%
Progression Free Survival
66%
Metastatic Carcinoma
66%
Malignant Neoplasm
50%
Neoadjuvant Chemotherapy
33%
Logistic Regression Analysis
16%
Retrospective Cohort Study
16%
Proportional Hazards Model
16%
Biopsy Technique
16%
Cancer Testis Antigen
16%
Immunotherapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Triple Negative Breast Cancer
100%
Progression Free Survival
66%
Malignant Neoplasm
50%
Chemotherapy
33%
Metastasis
33%
Cohort Study
16%
Cancer Testis Antigen
16%
Immunotherapy
16%
Immunology and Microbiology
Progression Free Survival
100%
Prognostic Biomarker
100%
Cancer Testis Antigen
25%
Immunotherapy
25%
Mathematics
Residuals
100%
Logistic Regression
33%
Cox Proportional Hazards Model
33%
Cancer Patient
33%
Biochemistry, Genetics and Molecular Biology
Progression Free Survival
100%
Cohort Study
25%